Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3042266 | 0.83 | KMT2A (0.41) | ALDH1A1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL13116574 | 0.79 | HPGD (0.68) | HPGDALDH1A1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL2880292 | 0.78 | MEN1 (0.37) | HPGDRAB9ASMN1; SMN2TP53CYP1A2 | |
| SCHEMBL12471307 | 0.75 | BRD4 (0.42) | HPGDALDH1A1RAB9ATP53CYP1A2 | |
| SCHEMBL128329 | 0.75 | MAPK1 (0.42) | ALDH1A1RAB9ASMN1; SMN2TP53CYP1A2 | |
| SCHEMBL27719491 | 0.75 | ALDH1A1 (0.69) | HPGDALDH1A1SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL30265358 | 0.75 | ALDH1A1 (0.69) | HPGDALDH1A1SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL9263348 | 0.74 | MMP13 (0.56) | HPGDALDH1A1SMN1; SMN2CYP1A2CYP2C19 | |
| Hydrochloric Acid SCHEMBL29898813 | 0.74 | ALDH1A1 (0.68) | HPGDALDH1A1SMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL29289764 | 0.74 | HPGD (0.61) | HPGDALDH1A1RAB9ASMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA (SE) | 2010-08-26 | — | — | US | disclosed |
| WO-2008020203-A1 | PYRIDINYLQUINAZ0LINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | BRAF, RAF1, ARAF | HPGD 1183/4885ALDH1A1 948/4885RAB9A 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.